Literature DB >> 29526653

Deep Vein Thrombosis Exhibits Characteristic Serum and Vein Wall Metabolic Phenotypes in the Inferior Vena Cava Ligation Mouse Model.

Yeji Sung1, Konstantina Spagou2, Marina Kafeza1, Michael Kyriakides2, Brahman Dharmarajah1, Joseph Shalhoub1, Jose A Diaz3, Thomas W Wakefield3, Elaine Holmes2, Alun H Davies4.   

Abstract

OBJECTIVES: Deep vein thrombosis (DVT) is a major health problem, responsible for significant morbidity and mortality. The identification of a simple and effective diagnostic biomarker of DVT remains a challenge. Metabolomics have recently emerged as a new powerful scientific tool to characterise metabolic phenotypes of complex diseases and investigate small molecules in biofluids. The aim of the study was to identify the blood and vein wall metabolomic signature of DVT in a murine experimental model.
METHODS: An established inferior vena cava ligation mouse model of DVT (n=10) was used and compared with sham surgery controls (n=10). Comprehensive untargeted metabolic profiling of serum and vein wall extracts was undertaken using liquid chromatography coupled mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy.
RESULTS: Multivariate and univariate statistical analysis demonstrated a differential metabolic profile when comparing DVT mice and control animals. Serum from DVT mice was characterised by differential concentrations of adenosine (decreased in DVT mice 9.6 fold), adenine (decreased 10.6 fold), and tricyclic acid cycle (TCA) intermediates, including citrate, succinate, and fumarate (1.5, 2.3, and 2.8 fold decreases, respectively). l-carnitine was found to be of greater abundance in the serum of DVT animals (67.0 fold change). A number of lipid moiety classes, including sphingomyelins, phosphatidylcholines, and triglycerides, were differentially abundant. Several metabolites were found in vein wall, including acetylcarnitine (increased in DVT mice 1.9 fold), adenosine (increased 2.2 fold), and ceramide (increased 2.7 fold). Correlation analysis illustrated the biochemical relationships between assigned metabolites, with the discriminatory molecules being highly correlated with each other, in both serum and vein wall.
CONCLUSIONS: The present findings demonstrate that metabolic dysregulations in DVT centre on energy metabolism, sphingolipid, and adenosine metabolism, representing a DVT specific metabolite signature in a murine experimental model.
Copyright © 2018 European Society for Vascular Surgery. All rights reserved.

Entities:  

Keywords:  Animal model; Biomarkers; Deep vein thrombosis; Metabolic profiling; Metabolomics; Venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 29526653     DOI: 10.1016/j.ejvs.2018.01.027

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  Effective prediction model for preventing postoperative deep vein thrombosis during bladder cancer treatment.

Authors:  Xing Liu; Abai Xu; Jingwen Huang; Haiyan Shen; Yazhen Liu
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

2.  Incidence and Risk Factors of Lower-Extremity Deep Vein Thrombosis After Thrombolysis Among Patients with Acute Ischemic Stroke.

Authors:  Chunping Ni; Xiuli Yan; Zhuo Liu; Dandan Liu; Zhen-Ni Guo; Hang Jin; Tong Sun
Journal:  Pharmgenomics Pers Med       Date:  2021-09-04

3.  [Plasma metabolomics in a deep vein thrombosis rat model based on ultra-high performance liquid chromatography-electrostatic field orbitrap high resolution mass spectrometry].

Authors:  Yan Gu; Peng Zang; Jinxia Li; Yanyan Yan; Jia Wang
Journal:  Se Pu       Date:  2022-08

4.  Serum Metabolic Profiles Based on Nuclear Magnetic Resonance Spectroscopy among Patients with Deep Vein Thrombosis and Healthy Controls.

Authors:  Melissa Quintero Escobar; Ljubica Tasic; Tassia Brena Barroso Carneiro da Costa; Danijela Stanisic; Silmara Montalvão; Stephany Huber; Joyce Maria Annichino-Bizzacchi
Journal:  Metabolites       Date:  2021-12-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.